WALTHAM,
Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies, today announced that the Company will host an
in-person investor event, along with a live webcast, on
Monday, December 9, 2024, at
7:00 a.m. PT/10:00 a.m. ET during the 66th American
Society of Hematology (ASH) Annual Meeting in San Diego, California. Members of the Syndax
management team will be joined by multiple key opinion leaders to
discuss data updates from the Company's revumenib and Niktimvo™
(axatilimab-csfr) programs.
A live webcast of the event will be available on the Investor
section of the Company's website at www.syndax.com, where a replay
of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage
biopharmaceutical company developing an innovative pipeline of
cancer therapies. Highlights of the Company's pipeline include
revumenib, a selective menin inhibitor, and Niktimvo™
(axatilimab-csfr), an FDA-approved monoclonal antibody that blocks
the colony stimulating factor 1 (CSF-1) receptor. Fueled by our
commitment to reimagining cancer care, Syndax is working to unlock
the full potential of its pipeline and is conducting several
clinical trials across the continuum of treatment. For more
information, please visit www.syndax.com/ or follow the Company on
X (formerly Twitter) and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-to-host-ash-investor-event-in-person-and-via-webcast-on-december-9-2024-302295973.html
SOURCE Syndax Pharmaceuticals, Inc.